Key points are not available for this paper at this time.
Abstract BACKGROUND Several human studies have demonstrated occurrence of two major collagen peptides, prolyl‐hydroxyproline (Pro‐Hyp) and hydroxyprolyl‐glycine (Hyp‐Gly), in human peripheral blood. Some in vitro studies have demonstrated that Pro‐Hyp and Hyp‐Gly exert chemotaxis on dermal fibroblasts and enhance cell proliferation. Additionally, Pro‐Hyp enhances the production of hyaluronic acid by dermal fibroblasts. These findings suggest that the amounts of Pro‐Hyp and Hyp‐Gly in blood are important factors to show the efficacy of collagen hydrolysates on skin health. RESULTS We conducted a randomised double‐blind placebo‐controlled clinical trial of ingestion of two types of collagen hydrolysates, which are composed of different amounts of the bioactive dipeptides Pro‐Hyp and Hyp‐Gly, to investigate their effects on the improvement of skin conditions. Improvement in skin conditions, such as skin moisture, elasticity, wrinkles, and roughness, were compared with a placebo group at baseline, and 4 and 8 weeks after the start of the trial. In addition, the safety of dietary supplementation with these peptides was evaluated by blood test. Collagen hydrolysate with a higher content of bioactive collagen peptides (H‐ CP ) showed significant and more improvement than the collagen hydrolysate with a lower content of bioactive collagen peptides (L‐ CP ) and the placebo, in facial skin moisture, elasticity ( R2 ), wrinkles and roughness, compared with the placebo group. In addition, there were no adverse events during the trial. CONCLUSION This study demonstrated that the use of the collagen hydrolysate with a higher content of Pro‐Hyp and Hyp‐Gly led to more improvement in facial skin conditions, including facial skin moisture, elasticity, wrinkles and roughness. © 2016 Society of Chemical Industry
Inoue et al. (Wed,) studied this question.